by uimmodulon_admin | 21st November 2019 | archive
Positive results from phase 1 follow up study supports current phase 2 clinical trial of IMM-101 in combination with checkpoint inhibitor therapy Immodulon, the immuno-oncology company, today announces that long-term survival data from its phase 1 study in 18 patients...
by Sandi Greenwood | 24th October 2019 | archive
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer | British Journal of Cancer (nature.com) Dalgleish, A., Stebbing, J., Adamson, D. et al. Randomised, open-label, phase II study of gemcitabine with and...
by uimmodulon_admin | 13th September 2019 | archive
Phase 1/2 study to investigate safety and efficacy of IMM-101 in locally advanced pancreatic cancer Uxbridge, UK, 13 September 2019 – Immodulon, the immuno-oncology company, today announces that the Department of Surgery at the Erasmus Medical Center in Rotterdam is...
by uimmodulon_admin | 8th August 2019 | archive
Professor Abila brings extensive experience in clinical drug development. Immodulon, the immuno-oncology company, announces the appointment of Professor Bams Abila, MD, PhD, FFPM, as Chief Medical Officer (CMO) of the Company with immediate effect. Professor Abila has...
by uimmodulon_admin | 25th July 2019 | archive
Biomarker Research for IMM-101 Utilizing the Biodesix Diagnostic Cortex™ Platform BOULDER, Colo. and UXBRIDGE, UK, July 25, 2019 – Biodesix Inc. and Immodulon Therapeutics Limited, the immune-oncology company, today announced that they have entered into a...
by uimmodulon_admin | 27th June 2019 | archive
Amsterdam, The Netherlands and Uxbridge, UK, 27 June, 2019 – myTomorrows, a Netherlands-based HealthTech company facilitating access to medicines in development and real-world data collection, and Immodulon, an immuno-oncology company, today announced a collaboration...